General
Preferred name
FOSAMPRENAVIR
Synonyms
Fosamprenavir (Calcium Salt) ()
FOSAMPRENAVIR CALCIUM ()
FOSAMPRENAVIR SODIUM ()
GW433908G ()
Amprenavir phosphate ()
GW 433908 ()
Fosamprenavir Calcium Salt ()
GW433908 ()
GW-433908 ()
GW433908A ()
GW 433908G ()
GW-433908G ()
Fosamprenavir calcium salt ()
Lexiva ()
Telzir ()
GW 433908A ()
GW-433908A ()
P&D ID
PD009566
CAS
226700-79-4
226700-81-8
226700-80-7
Tags
available
drug candidate
prodrug
drug
Approved by
FDA
First approval
2003
Drug Status
approved
Drug indication
Human immunodeficiency virus infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Fosamprenavir is hydrolyzed by cellular phosphatases to the antiretroviral protease inhibitor amprenavir. This hydrolysis allows for the slow release of amprenavir, reducing the number of pills a patient must take.
DESCRIPTION
Fosamprenavir is a prodrug of the HIV-1 protease inhibitor and antiretroviral drug .
(GtoPdb)
DESCRIPTION
HIV protease inhibitor; water soluble prodrug of amprenavir.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
17
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
67
Molecular Weight
585.19
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
4
Rotatable Bonds
13
Ring Count
3
Aromatic Ring Count
2
cLogP
2.52
TPSA
177.72
Fraction CSP3
0.48
Chiral centers
3.0
Largest ring
6.0
QED
0.2
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
human immunodeficiency virus (HIV-1)
MOA
HIV Protease inhibitor
Therapeutic Class
Anti-HIV Agents
Pathway
Anti-infection
Metabolic Enzyme/Protease
Target
Endogenous Metabolite
HIV
HIV Protease
Solubility
In Vitro:<br/>DMSO : 50 mg/mL(80.17 mM
Need ultrasonic)<br/>H2O : 0.25 mg/mL(0.40 mM
Need ultrasonic and warming)<br/>In Vivo:<br/>1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline<br/>Solubility: ≥ 2.5 mg/mL (4.01 mM)
Clear solution<br/>2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline)<br/>Solubility: ≥ 2.5 mg/mL (4.01 mM)
Clear solution<br/>3.Add each solvent one by one:10% DMSO >> 90%corn oil<br/>Solubility: ≥ 2.5 mg/mL (4.01 mM)
Clear solution
Source data
